Management of Hyperglycemia in Kidney Failure

DPP-4 Inhibitor Options

Linagliptin is the preferred substitute for sitagliptin in patients with kidney failure, as it requires no dose adjustment regardless of renal function, according to the American Diabetes Association 1, 2
Sitagliptin can still be used in kidney failure but requires significant dose reduction, with a 50% dose reduction for eGFR 30-50 mL/min/1.73m² and a 75% dose reduction for eGFR <30 mL/min/1.73m² 2
Vildagliptin should be avoided in patients on hemodialysis or with advanced CKD, as recommended by the National Kidney Foundation 2

Gliclazide is a second-generation sulfonylurea that can be safely used in kidney failure, with a lower initial dose and cautious titration to avoid hypoglycemia, according to the European Association for the Study of Diabetes 3
Repaglinide is another option for patients with kidney failure, with a starting dose of 0.5mg with meals if eGFR <40 mL/min/1.73m² and careful titration, as recommended by the American College of Clinical Pharmacology 2
Pioglitazone requires no dose adjustment in kidney failure but should be used with caution due to increased risk of fluid retention and heart failure, according to the American Heart Association 1, 2

Metformin is contraindicated in advanced kidney disease due to risk of lactic acidosis, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 2
Acarbose should be avoided if serum creatinine >2 mg/dL, and Miglitol should be avoided if eGFR <25 mL/min/1.73m², according to the European Medicines Agency 2
Exenatide should be avoided if eGFR <30 mL/min/1.73m², as recommended by the American Association of Clinical Endocrinologists 2

More frequent blood glucose monitoring is essential in kidney failure patients on any antidiabetic medication, with consideration of less stringent glycemic targets (HbA1c ~7.0%) for patients at risk of hypoglycemia, according to the International Society for Pediatric and Adolescent Diabetes 3
HbA1c may be less reliable in advanced kidney disease, and monitoring for drug interactions is crucial, particularly when combining with other medications that may increase hypoglycemia risk, as recommended by the American Society of Health-System Pharmacists 3